Midwest Financial Partners Investments Inc. bought a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,186 shares of the company’s stock, valued at approximately $5,944,000. ARK Genomic Revolution ETF comprises approximately 3.3% of Midwest Financial Partners Investments Inc.’s investment portfolio, making the stock its 11th biggest position. Midwest Financial Partners Investments Inc. owned approximately 0.46% of ARK Genomic Revolution ETF as of its most recent SEC filing.
Several other large investors have also added to or reduced their stakes in ARKG. Krilogy Financial LLC acquired a new position in ARK Genomic Revolution ETF during the third quarter worth $5,806,000. Jump Financial LLC acquired a new position in ARK Genomic Revolution ETF during the third quarter worth $4,563,000. Canal Insurance CO acquired a new position in ARK Genomic Revolution ETF during the fourth quarter worth $3,476,000. Group One Trading LLC bought a new position in ARK Genomic Revolution ETF in the second quarter valued at approximately $2,274,000. Finally, Woodline Partners LP bought a new position in ARK Genomic Revolution ETF in the third quarter valued at approximately $2,071,000.
ARK Genomic Revolution ETF Stock Performance
ARKG stock opened at $30.53 on Friday. The business has a 50 day moving average price of $28.32 and a two-hundred day moving average price of $29.33. ARK Genomic Revolution ETF has a twelve month low of $20.26 and a twelve month high of $34.39.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Featured Articles
- Five stocks we like better than ARK Genomic Revolution ETF
- Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending
- As Small-Cap Outperformance Continues, These 2 ETFs Provide Exposure
- Silicon Shake-Up: The AI Trade Is Moving Beyond NVIDIA
- The Silver Lining of Last Week’s Hims & Hers Earnings Miss
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
